CTI BioPharma Corp. (CTIC)

0.92
NASDAQ : Health Technology
Prev Close 0.89
Day Low/High 0.86 / 0.92
52 Wk Low/High 0.60 / 2.30
Avg Volume 241.80K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 51.34M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Affymax

Biotech Stock Mailbag: Affymax

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

10 Best Mutual Funds for 2012

10 Best Mutual Funds for 2012

Ten funds rise to the top of our fund model rankings and warrant consideration for inclusion in your fund portfolio for 2012.

Biotech Stock Mailbag: Exelixis

Biotech Stock Mailbag: Exelixis

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Preview: A Busy Week for Biotech Earnings

Preview: A Busy Week for Biotech Earnings

All four of the largest biotech stocks -- Celgene, Amgen, Biogen Idec and Gilead Sciences -- report third-quarter earnings this week.

Biotech Stock Mailbag: Keryx Pharma

Biotech Stock Mailbag: Keryx Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

When 'Accelerated' FDA Reviews Are Slow

When 'Accelerated' FDA Reviews Are Slow

Talon Therapeutics learns that FDA can review its cancer drug under accelerated review but still take its own sweet time.

Cell Stock Hits New 52-Week Low (CTIC)

Cell Stock Hits New 52-Week Low (CTIC)

Cell Therapeutics (Nasdaq:CTIC) hit a new 52-week low Wednesday as it is currently trading at $1.25, below its previous 52-week low of $1.26 with 393,889 shares traded as of 10:47 a.m. ET. Average volume has been 2.5 million shares over the past 30 days.

Cell Stock Gaps Down On Today's Open (CTIC)

Cell Stock Gaps Down On Today's Open (CTIC)

Shares of Cell Therapeutics (Nasdaq:CTIC) were gapping down Thursday morning with an open price 15.3% lower than Wednesday's closing price. The stock closed at $1.96 yesterday and opened today's trading at $1.66.

Biotech Data Mining Comes Up Empty

Biotech Data Mining Comes Up Empty

Apricus and Cel-Sci are the latest biotech companies to cover up clinical trial problems with dubious scientific analyses.

Biotech Calendar: 2011 FDA Drug Approvals

Biotech Calendar: 2011 FDA Drug Approvals

An updated list of drug and biotech firms with drug approvals expected in 2011.

Biotech Stock Mailbag: Neoprobe

Biotech Stock Mailbag: Neoprobe

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Cell Therapeutics: Cancer Drug Rejected Again

Cell Therapeutics: Cancer Drug Rejected Again

FDA refuses to allow Cell Therapeutics to market its cancer drug, which puts the company on track for another reverse stock split.

Biotech Stock Mailbag: Bio-Hazards

Biotech Stock Mailbag: Bio-Hazards

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Cell Stock Falls On Unusually High Volume (CTIC)

Cell Stock Falls On Unusually High Volume (CTIC)

Cell Therapeutics (Nasdaq:CTIC) is trading at unusually high volume Friday with 58 million shares changing hands. It is currently at 8.9 times its average daily volume and trading down one cent (-2.5%).

Biotech Stock Mailbag: Star Scientific

Biotech Stock Mailbag: Star Scientific

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Cell Stock Gaps Down On Today's Open (CTIC)

Cell Stock Gaps Down On Today's Open (CTIC)

Shares of Cell Therapeutics (Nasdaq:CTIC) were gapping down Friday morning with an open price 10.7% lower than Thursday's closing price. The stock closed at 28 cents yesterday and opened today's trading at 25 cents.

Biotech Calendar: Key Dates for March

Biotech Calendar: Key Dates for March

Here's a list of March's potentially stock-moving biotech events.

Biotech Mailbag: BIO CEO Wrap

Biotech Mailbag: BIO CEO Wrap

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

BIO CEO Conference Live Blog: Day 2

BIO CEO Conference Live Blog: Day 2

TheStreet's Adam Feuerstein blogs a conference in New York for smaller biotechs.

Biotech Stock Mailbag: Vical

Biotech Stock Mailbag: Vical

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

15 Biotech Stock Predictions for 2011

15 Biotech Stock Predictions for 2011

Adam Feuerstein peers into his crystal ball to offer somewhat improbable yet highly surprising biotech stock predictions for the coming year.

Worst Biotech CEO of 2010 Is...

Worst Biotech CEO of 2010 Is...

TheStreet's readers picked Amylin's Dan Bradbury as the worst biotech CEO of the year.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.

Dumbest of This Week's 5 Dumbest: The Never Ending Fannie-Freddie Bailout

Dumbest of This Week's 5 Dumbest: The Never Ending Fannie-Freddie Bailout

About 38% of voters find it dumb that the government continues to bailout Fannie Mae and Freddie Mac.

The 5 Dumbest Things on Wall Street: Oct. 22

The 5 Dumbest Things on Wall Street: Oct. 22

Here is this week's roundup of the dumbest actions on Wall Street.

Cell Therapeutics: Empty Promises

Cell Therapeutics makes chronic excuses for failing to deliver a European approval filing for its lymphoma drug.

Biotech Stock Mailbag: Vivus

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Dumbest of This Week's 5 Dumbest: Cell Therapeutics Has No Shame

Dumbest of This Week's 5 Dumbest: Cell Therapeutics Has No Shame

About 44% of voters are outraged that Cell Therapeutics CEO Jim Bianco asked shareholder for approval to wildly increase the number of company shares.

The 5 Dumbest Things on Wall Street: Sept. 17

The 5 Dumbest Things on Wall Street: Sept. 17

This week's roundup of the dumbest actions on Wall Street.

TheStreet Quant Rating: D (Sell)